

**LIFESTYLE, BODY FAT DISTRIBUTION
AND INSULIN-RELATED CORONARY HEART DISEASE RISK
FACTORS IN HYPERTENSIVE FEMALES**

by

Louwrens Andries Stephanus du Plessis

Submitted in partial fulfilment of the requirements for the degree

D. Phil. (Human Movement Science)

in the

Faculty of Humanities

University of Pretoria

PRETORIA

September 2000



ACKNOWLEDGEMENTS

The author wants to thank the following persons who made this study possible:

- God, my heavenly Father, who gave me inner strength
- My promotor, Prof. J.M.. Loots, for his guidance and sempiternal patience
- My wife Sonia, for her moral support and endless help on the computer
- Mrs. Rita Olwagen, for her assistance with the statistical analysis
- Mr. Ian Cook and Dr. Sanette Brits, for their support and encouragement
- Dr. Mariaan Alberts and Dr. Tessa van der Merwe, for their advice on the blood tests
- Dr. Willie Kamffer and Dr. Henk Stander, for the sonars and scans
- Mrs. Carol-Lynn Nel, for her editing of the script
- Jani and Imé, my two daughters, who had to sacrifice so much

CONTENTS

	PAGE
CHAPTER 1	
INTRODUCTION	
1.1 Historical background	1
1.2 The cost of hypertensive treatment and the role of lifestyle modification	4
1.3 The aims of the present study	9
CHAPTER 2	
LITERATURE STUDY	
2 General outlay of the literature study	10
2.1 The prevalence of hypertension in females	10
2.1.1 Racial differences	12
2.2 Complications of hypertension	12
2.2.1 Effect of gender	13
2.2.2 Effect of race	14
2.2.3 Effect of age	15
2.2.4 Effect of ambulatory pressure	16
2.3 Possible causes of hypertension	16
2.3.1 Age	16
2.3.2 Environmental factors	17
2.3.3 Obesity	18
2.3.4 Leptin	20
2.3.5 Alcohol	23
2.3.6 Smoking	23
2.3.7 Sodium intake	24
2.3.8 Potassium intake	26
2.3.9 Calcium intake	27
2.3.10 Fat intake	28
2.3.11 Dyslipidaemia	30
2.3.11.1 Effects of serum lipids on blood pressure	31
2.3.12 Physical inactivity	32
2.3.13 Psychological factors	35
2.3.14 Low birth mass	36
2.4 Pathophysiology of hypertension	36
2.4.1 Neurogenic hypertension	37
2.4.1.1 Sensing of excess body salt by the central nervous system	38
2.4.1.2 Blood pressure seeking behavior of the central nervous system	38
2.4.1.3 Sympathetic activity and hemodynamic transitions	39
2.4.2 Renal hemodynamics and hypertension	40
2.4.2.1 Renal function curve	40
2.4.2.2 Salt loading and the renal function curve	42

2.4.2.3	The effect of race on salt sensitivity	45
2.4.2.4	Obesity and salt sensitivity	46
2.4.2.5	Plasma atrial natriuretic peptide (ANP) and salt sensitivity	48
2.4.2.6	The renin angiotensin system and salt sensitivity	49
2.4.3	Endothelial dysfunction and hypertension	52
2.4.3.1	Endothelium derived relaxing factor (EDRF)	54
2.4.3.2	Prostacyclin	55
2.4.3.3	Endothelin-1	56
2.4.4	Insulin resistance and hypertension	58
2.4.4.1	Evidence linking insulin resistance and hypertension	58
2.4.4.2	Mechanisms by which insulin resistance may cause hypertension	60
2.4.4.2.1	Insulin resistance and increased sympathetic nervous system activity	60
2.4.4.2.2	Sympathetic nervous system (SNS) and secondary insulin resistance	62
2.4.4.2.3	Increased renal sodium re-absorption	63
2.4.4.2.4	Disturbed membrane ion transport	64
2.4.4.2.5	Hypertrophy of the vascular wall	65
2.4.4.3	Reservations about the insulin resistance theory	66
2.5	What causes insulin resistance?	67
2.5.1	Lifestyle and insulin resistance	68
2.5.1.1	Physical inactivity	70
2.5.1.2	Fat intake	70
2.5.2	Obesity and Insulin resistance	73
2.5.2.1	Lipolytic sensitivity of visceral fat	77
2.5.2.2	A hypersensitive hypothalamo-pituitary adrenal (HPA) axis and lipolytic sensitivity	78
2.5.2.3	Anti lipolytic effect of insulin in the intraperitoneal fat depot	80
2.5.2.3.1	The effect of race on the antilipolytic effect of insulin	80
2.5.3	Hepatic removal of insulin	81
2.5.4	Smoking	82
2.5.5	Muscle morphology	83
2.6	Coronary heart disease risk factors in hypertensive patients with insulin resistance	85
2.6.1	Hyperinsulinaemia	86
2.6.1.1	Insulin resistance and CHD in different race groups	87
2.6.2	Non insulin dependent diabetes mellitus	87
2.6.2.1	What causes the link between diabetes and CHD?	89
2.6.3	Smoking	92
2.6.4	Central obesity	93
2.6.5	Dyslipidaemia	95
2.6.5.1	LDL cholesterol	97
2.6.5.1.1	The size of LDL particles	99
2.6.5.1.2	The relation between LDL particle size and insulin resistance	100

2.6.5.1.3	Hyperapo B and adipocyte malfunctioning	101
2.6.5.2	High density lipoprotein cholesterol	104
2.6.5.2.1	The antiatherosclerotic effect of HDL	104
2.6.5.2.2	Reverse cholesterol transport	105
2.6.5.2.3	Anti atherosclerotic properties of HDL not associated with reverse cholesterol transport	107
2.6.5.2.4	What is the link between insulin resistance and low HDL cholesterol levels?	108
2.6.5.3	Triglyceride	110
2.6.5.3.1	Hypertriglyceridaemia as part of the insulin resistance syndrome	110
2.6.5.3.2	Triglyceride and coronary heart disease	112
2.6.5.3.3	Triglyceride and the scavenger pathway	113
2.6.5.3.4	Reservations about the role of triglyceride in atherosclerosis	117
2.6.6	Fibrinolysis	118
2.6.6.1	Fibrinolysis and plasminogen activator inhibitor-I (PAI I)	121
2.6.6.1.1	Plasminogen activator inhibitor-I as part of the insulin resistance syndrome	122
2.6.6.2	Fibrinogen and coronary heart disease	124
2.6.6.3	The relation between insulin and fibrinogen	125
2.6.7	Hyperuricaemia	125
2.6.7.1	Hyperuricaemia and coronary heart disease	127
2.6.8	Microalbuminuria	128
2.6.8.1	Endothelial dysfunction as the underlying pathogenic mechanism of microalbuminuria and insulin resistance	128
2.6.8.2	Microalbuminuria and CHD	130

CHAPTER 3 METHODOLOGY

3.1	Subjects	132
3.2	Methods	132
3.2.1	First Interview	132
3.2.2	First Appointment	133
3.2.3	Anthropometry	133
3.2.3.1	Body density of black subjects	133
3.2.3.2	Body density of white subjects	134
3.2.3.3	Additional calculations of body density	134
3.2.3.4	Sagittal height	136
3.2.4	Ultrasound measurements	136
3.2.5	Computed tomography scan measurements	137
3.2.6	Blood pressure measurement	137
3.2.7	Rockport walking test	138
3.2.8	Lifestyle and health assessment	140
3.2.9	Dietary analysis	144
3.2.10	Psychometric testing	145

3.2.11	Blood Tests	146
3.2.12	Statistical analysis	148
3.2.12.1	Descriptive statistics	148
3.2.12.2	Comparisons between black and white subjects	149
3.2.12.3	Comparisons between subgroups within a group	150
3.2.12.4	Relation between variables	150
3.2.12.5	Describing relations between variables	151

CHAPTER 4

RESULTS AND DISCUSSION

4.1	Socio-economic status and family history	154
4.1.1	Psychological profiles	154
4.1.2	Birthmass	155
4.2	Relation between body composition, abdominal fat measurements and lifestyles	157
4.2.1	Aerobic capacity and visceral fat accumulation	162
4.2.2	Relation between computed tomography, ultrasound and anthropometric measurements of abdominal fat	164
4.3	Relation between visceral fat measurements and metabolic risk factors	171
4.4	Blood pressure and body mass control	175
4.4.1	Energy balance and body mass	180
4.4.2	Isolated systolic hypertension	184
4.4.3	White coat hypertension	185
4.4.4	Relation between anti-hypertensive drugs and the control of blood pressure and metabolism in white subjects	186
4.4.5	Relation between anti-hypertensive drugs and the control of blood pressure and metabolism in black subjects	190
4.4.6	Family history and blood pressure control	194
4.4.7	Diet and blood pressure control	195
4.4.7.1	Sodium	195
4.4.7.2	Potassium	197
4.4.7.3	Linoleic acid	201
4.4.7.4	Fish consumption	202
4.4.7.5	Vitamin E and C	203
4.4.7.6	Selenium	205
4.4.7.7	Protein and vitamin B intake	207
4.4.8	Blood pressure and metabolic control in relation to physical activity and aerobic capacity	211
4.4.8.1	Beta blockers and aerobic capacity	220
4.5	Lipid profiles	224
4.5.1	Total cholesterol	224
4.5.1.1	Cholesterol in relation to obesity	229
4.5.1.2	Diet and cholesterol levels	231
4.5.2	Low density lipoprotein cholesterol	234

4.5.2.1	Diet and LDL cholesterol levels	238
4.5.2.2	LDL cholesterol and Apoprotein B	240
4.5.2.3	LDL particle size and anti-oxidant intake	244
4.5.3	Lipoprotein (a)	246
4.5.3.1	Fibrinogen	250
4.5.4	High density lipoprotein cholesterol	253
4.5.4.1	HDL cholesterol and Apo A I	255
4.5.4.2	HDL/Total cholesterol ratio	258
4.5.5	Triglyceride	262
4.6	Leptin	267
4.7	Glucose	269
4.8	Insulin and insulin resistance	278
4.9	Uric acid	283
4.10	Microalbuminuria	287
4.11	Clustering of metabolic CHD risk factors	291

CHAPTER 5

CONCLUSIONS AND RECOMMENDATIONS

5.1	Conclusions	301
5.2	Recommended lifestyle modifications	305
5.2.1	Exercise, diet and body mass	307
5.2.2	Dietary recommendations	312
5.3	Recommendations for future research	318

REFERENCES

321

LIST OF TABLES

	Page	
Table 1.1	The effect of lifestyle modification on blood pressure and CHD risk (Beilin, 1994)	6
Table 2.1	Essential fatty acid metabolism, desaturation and elongation of omega-6 and omega 3 series	31
Table 4.1	Comparison of lifestyle factors, anthropometric measurements and abdominal fat distribution in black and white subjects	158
Table 4.2	Visceral fat areas in black and white South-African subjects	163
Table 4.3	Separate regressing of visceral fat areas in black and white subjects on potential surrogate measurements of visceral fat	165
Table 4.4	Regression analysis of visceral fat on surrogate measurements of visceral fat in black and white subjects	168
Table 4.5	Correlation matrix of visceral fat areas and insulin resistance related metabolic disturbances in black and white subjects	171
Table 4.6	Correlation matrix of surrogate measurements of visceral fat and insulin resistance related metabolic disturbances in black and white subjects	172
Table 4.7	Comparison of blood pressure, energy intake, energy expenditure, leptin levels and body mass control in black and white subjects	176
Table 4.8	Significance of the differences in metabolic profiles of white subjects using different types of anti-hypertensive drugs	187
Table 4.9	Metabolic profiles of white subjects whose blood pressure were under control with anti-hypertensive drugs in comparison to that of subjects with uncontrolled blood pressure	188
Table 4.10	Clustering of metabolic CHD risk factors in 5 white subjects whose blood pressure were uncontrolled with Ace inhibitors or Ace inhibitor diuretic combinations	189
Table 4.11	Metabolic profiles of 4 black subjects who had large metabolic risk clusters and uncontrolled blood pressure	193
Table 4.12	Comparison of dietary aspects related to blood pressure control and CHD risk in black and white subjects	196
Table 4.13	Comparison of activity levels, aerobic capacities, blood pressure and metabolic control in black and white subjects	212
Table 4.14	Comparison of age, blood pressure, heart rates during 1 mile walk, walking times and estimated maximal oxygen consumption in black and white subjects who used β -	223

	blockers	
Table 4.15	Comparison of diets, blood lipids and fibrinolytic factors in black and white subjects	225
Table 4.16	Categorization of subjects into CHD risk categories according to age and cholesterol levels	227
Table 4.17	Cholesterol cut-off points as recommended by the South-African Heart Foundation	228
Table 4.18	LDL cholesterol cut-off points as recommended by the South-African Heart Foundation (Rossouw <i>et al.</i> , 1988)	235
Table 4.19	LDL cholesterol cut-off points for different age groups as recommended by the VIGHOR investigators (Vermaak <i>et al.</i> , 1991)	336
Table 4.20	Comparison of fat intakes between black and white subjects with normal and elevated LDL cholesterol levels	239
Table 4.21	Comparison of apo B levels and LDL particle size in subjects with low and high LDL cholesterol levels	242
Table 4.22	Comparison of diet, aerobic capacity and obesity level in black and white subjects with low HDL to Total cholesterol levels	259
Table 4.23	Comparison of insulin resistance and some of its associated metabolic disturbances in black and white subjects	263
Table 4.24	Comparison of metabolic disturbances in 3 subgroups of subjects with different serum triglyceride levels	264
Table 4.25	Correlations between leptin levels and body fat measurements of black and white subjects	267
Table 4.26	Prevalence of Type 2 diabetes in black hypertensive populations in South-Africa	269
Table 4.27	Metabolic risk factors for diabetes in black and white subjects in comparison to that of females who maintained glucose tolerance or who converted to type 2 diabetes over a 8 year follow-up period (Haffner, Miettinen & Stern, 1997)	270
Table 4.28	Central fat measurements of black subjects with normal fasting glucose levels compared to that of diabetic subjects	272
Table 4.29	Confounder variables that were not included in a multiple linear regression model of central fat and fasting glucose levels in black subjects	274
Table 4.30	Diabetes risk factors in white subjects with suspected microalbuminuria	289
Table 4.31	Percentages of black and white subjects with metabolic disturbances that are frequently associated with the insulin resistance or metabolic syndrome	292
Table 4.32	Metabolic profiles of black subjects with metabolic risk clusters which include 3 or more metabolic disturbances	293

	Page
2.1	21
2.2	22
2.3	23
2.4	23
2.5	24
2.6	25
2.7	25
2.8	26
2.9	26
2.10	27
2.11	27
2.12	28
2.13	28
2.14	29
2.15	29
2.16	30

(note that the thickness of the arrows indicates a more or less increased action; 1 = decreased action) (adapted from *et al.*, 1996)

LIST OF FIGURES

	Page
FIG. 2.1	Cascade of central obesity and its complications (reprinted with permission from Van der Merwe, 1997 a) 21
FIG. 2.2	Schematic representation of biologic responses to leptin (adapted from Friedman, 1998) 22
FIG. 2.3	Coronary artery disease in relation to fat consumption through the ages (adapted from Simopoulos 1991) 30
FIG. 2.4	The anti- hypertensive effects of exercise on the central nervous system 33
FIG. 2.5	Renal-fluid volume mechanism for control of blood pressure (adapted from Guyton <i>et al.</i> , 1990) 41
FIG. 2.6	Comparison between the isolated kidney renal function curve and the salt - loading renal function curve at normal and high salt intake (adapted from Guyton <i>et al.</i> , 1990) 43
FIG. 2.7	Schematic representation of the mechanisms involved in the sensing of blood volume changes and the control of sodium and water retention or excretion (adapted from Cowley, 1997) 44
FIG. 2.8	Possible mechanisms by which altered renal medullary histology and activation of the sympathetic and renin angiotensin systems may contribute to hypertension in obese subjects (Adapted from Hall, 1997) 47
FIG. 2.9	Postulated mechanisms by which vascular and endothelium derived angiotensin may affect the contractile state of blood vessels 51
FIG. 2.10	Vasoactive substances that are released by the endothelium 53
FIG. 2.11	Postulated relation between insulin resistance, sympathetic nervous system activity and hypertension (adapted from DeFronzo & Ferraninni, 1991) 62
FIG. 2.12	Putative causes of insulin resistance and its associated metabolic disturbances (adapted from Bouchard, 1995) 69
FIG. 2.13	Substrate competition between free fatty acids and glucose for the same oxidation pathway in skeletal muscle 72
FIG. 2.14	Non-esterified fatty acids as the central feature of the insulin resistance syndrome or metabolic syndrome (adapted from Frayn <i>et al.</i> , 1996) 75
FIG. 2.15	Circadion variation in plasma NEFA concentrations of subjects with (red) and without (blue) type 2 diabetes (adapted from Reaven <i>et al.</i> , 1988) 76
FIG. 2.16	Regional differences in the regulation of adipocyte lipolysis (note that the thickness of the arrows indicate amounts: ↑ = increased action; ↓ = decreased action) (adapted form Frayn <i>et al.</i> , 1996) 79

FIG. 2.17	Diagrammatic representation of lipoprotein metabolism (adapted from Oberman <i>et al.</i> , 1992)	91
FIG. 2.18	The effect of insulin on the liver, skeletal muscle and adipose tissue	96
FIG. 2.19	Relation between lipid infiltration and endothelial injury in the development of atherosclerosis (adapted from Oberman <i>et al.</i> , 1992)	99
FIG. 2.20	Fatty acid metabolism in adipose tissue in the postprandial period (adapted from Frayn <i>et al.</i> , 1996)	102
FIG. 2.21	Schematic representation of reverse cholesterol transport	106
FIG. 2.22	Sources of HDL constituents (adapted from Oberman <i>et al.</i> , 1992)	109
FIG. 2.23	Receptor mediated pathways for the removal of LDL from the circulation (adapted from Oberman <i>et al.</i> , 1992)	114
FIG. 2.24	Schematic diagram of the structure and composition of VLDL and LDL lipoprotein particles (adapted from Oberman <i>et al.</i> , 1992)	116
FIG. 2.25	Comparison of ischaemic heart disease rates in USA males and females between 1980 and 1990 (adapted from Hussain <i>et al.</i> , 1996)	120
FIG. 2.26	Changes in veno-arterial concentration of PAI- I antigen during infusion of insulin (100 μ IU/ml of plasma) (adapted from Morale <i>et al.</i> , 1997)	123
FIG. 2.27	Schematic representation of the association between lifestyle, insulin resistance and cardiovascular disease	131
FIG. 3.1	Blood pressure recordings of a 50 year old white female with hypertension	139
FIG. 3.2	Line drawings of 9 females with progressive levels of body fat (adapted from Paffenbarger <i>et al.</i> , 1993)	141
FIG. 3.3	Basal homeostasis model assessment (HOMA) (adapted from Matthews, Hosker, Rudenski, Naylor, Treacher & Turner, 1985)	149
FIG. 3.4	Regression lines showing differences between measured visceral fat areas (dots) and visceral fat areas as predicted from intraabdominal fat layers and WHRs	152
FIG. 4.1	Scatterplot of birthmass and body mass index in black and white subjects	155
FIG. 4.2	Family history of hypertension and diabetes in black and white subjects	156
FIG. 4.3	Graphic example of the effect of persistently elevated cortisol levels on central fat accumulation	160
FIG. 4.4	Comparison of subcutaneous abdominal fat areas in a black and a white subject with similar visceral fat areas	161
FIG. 4.5	Relation between aerobic capacities and visceral fat areas in black and white subjects	162
FIG. 4.6	Relation between body mass index and visceral fat areas in	164

	black and white subjects	
FIG. 4.7	Relation between intra-abdominal sonar and computed tomography measurements of visceral fat in white subjects	166
FIG. 4.8	Relation between sonar measurements of subcutaneous abdominal fat and computed tomography scans of visceral fat in black subjects	167
FIG. 4.9	Ultrasound measurement of subcutaneous abdominal and intra-abdominal fat in 2 black diabetic subjects	170
FIG. 4.10	Anatomy and nomenclature of abdominal fat depots (adapted from Van der Kooy & Seidell, 1993)	173
FIG. 4.11	Computed tomography scans of 2 subjects who had approximately similar visceral fat areas but unequal distributions of intra and extraperitoneal fat	174
FIG. 4.12:	Scatterplot of diastolic and systolic blood pressure in black and white subjects	175
FIG. 4.13	Body mass loss of black subjects the last year before the present study	177
FIG. 4.14	Body mass loss of white subjects the last year before the present study	178
FIG. 4.15:	Estimated body mass losses of white subjects over the course of their adult lives	179
FIG. 4.16	Estimated body mass losses of black subjects over the course of their adult lives	179
FIG. 4.17	Scatterplot of estimated energy balance and body mass indexes of black and white subjects	181
FIG. 4.18	Fat intakes of "underreporters" and "true reporters" in the present study in comparison to other black and white South-African females	182
FIG. 4.19	Twenty four hour heart rate pattern of an obese white subject	183
FIG. 4.20	Anti - hypertensive drugs used by white subjects	186
FIG. 4.21	Blood pressure control in white subjects who used ACE inhibitors and ACE inhibitor diuretic combinations	187
FIG. 4.22	Scatterplot of metabolic and blood pressure control in white subjects	189
FIG. 4.23	Anti-hypertensive drugs used by black subjects	190
FIG. 4.24	Blood pressure control in black subjects who used diuretics or a combination of diuretics and β - blockers	191
FIG. 4.25	Comparison of HDL cholesterol levels between black subjects whose blood pressure were controlled or uncontrolled with anti-hypertensive drugs	192
FIG. 4.26	Scatterplot of the number of metabolic risk factors and blood pressure control in black subjects who large metabolic risk clusters	193
FIG. 4.27	Comparison between blood pressure control and family histories of hypertension in black and white subjects	194

FIG. 4.28	Scatterplot of sodium consumption and blood pressure control in black and white subjects	197
FIG. 4.29	Potassium and sodium consumption in relation to blood control in black subjects	198
FIG. 4.30	Sodium potassium consumption ratios in black and white South-African females	199
FIG. 4.31	Scatterplot of potassium and sodium consumption and blood pressure control in white subjects	200
FIG. 4.32	Relation between linoleic acid consumption and blood pressure control in black subjects	201
FIG. 4.33	Relation between linoleic acid consumption and blood pressure control in white subjects	202
FIG. 4.34	Alpha-linolenic consumption and blood pressure in black and white subjects	203
FIG. 4.35	Scatterplot of vitamin E and polyunsaturated fat consumption in black and white subjects	204
FIG. 4.36	Vitamin E and C consumption of black and white subjects in comparison to RDA values	206
FIG. 4.37	Scatterplot of animal and plant protein consumption in black and white subjects	208
FIG. 4.38	Scatterplot of protein and vitamin B ₆ consumption in black and white subjects	209
FIG. 4.39	Folic acid and vitamin B ₁₂ consumption in black and white subjects	210
FIG. 4.40	General activity levels of black and white subjects	213
FIG. 4.41	Scatterplot of daily energy expenditure and Functional Aerobic Impairment in black and white subjects	214
FIG. 4.42	Scatterplot of age and FAI status of black and white subjects with above average aerobic capacities	215
FIG. 4.43	The number of metabolic risk factors and blood pressure control in black and white subjects with above average aerobic capacities	215
FIG. 4.44	The number of metabolic risk factors and blood pressure control in black and white subjects with below average aerobic capacities	217
FIG. 4.45	Daily activity pattern of white subjects	218
FIG. 4.46	Daily activity pattern of black subjects	219
FIG. 4.47	Relation between expected and indirectly measured oxygen consumption in white subjects	221
FIG. 4.48	Relation between expected and indirectly measured oxygen consumption in black subjects	222
FIG. 4.49	Cholesterol levels of black and white South-African females from different regions	226
FIG. 4.50	Correlation between body mass indexes and serum cholesterol levels in black subjects	230
FIG. 4.51	Correlation between body mass indexes and serum	231

	cholesterol levels in white subjects	
FIG. 4.52	Scatterplot of saturated fat intake and cholesterol levels in black and white subjects	232
FIG. 4.53	Correlation between stearic acid intake and cholesterol levels in black subjects after removal of 3 outliers	233
FIG. 4.54	Comparison of SA Heart Foundation recommended LDL cholesterol cut-off points and LDL cholesterol levels of white South - Africans as measured in the VIGHOR study (Vermaak <i>et al.</i> , 1991)	235
FIG. 4.55	Categorization of subjects into CHD risk categories according to their LDL cholesterol levels	237
FIG. 4.56	Percentage of subjects with low or high risk LDL cholesterol levels in comparison to the percentages from countries with high and low prevalence of CHD	238
FIG. 4.57	Scatterplot of saturated fat intake and LDL cholesterol levels in subjects with high LDL cholesterol levels	240
FIG. 4.58	Correlation between apo B and LDL cholesterol levels in black and white subjects	241
FIG. 4.59	Estimated LDL particle sizes in white females from different populations	243
FIG. 4.60	Correlation between triglyceride levels and LDL particle size in white subjects with low LDL cholesterol levels	244
FIG. 4.61	Comparison of Lp (a) levels in black and white subjects	247
FIG. 4.62	Scatterplot of Lp(a) and LDL cholesterol in black and white subjects with Lp(a) levels higher than 30 mg/dl	247
FIG. 4.63	Scatterplot of plasminogen activity and fibrinogen levels in black subjects with Lp (a) levels higher and lower than 30 mg/dL	249
FIG. 4.64	Comparison of fibrinogen levels in black and white subjects	250
FIG. 4.65	Scatterplot of Lp (a) and fibrinogen levels in black and white subjects with fibrinogen levels higher than 4 g/L	251
FIG. 4.66	Comparison of carbohydrate intakes in black and white South-African females	252
FIG. 4.67	Scatterplot of age and HDL cholesterol levels in 40 to 50 year old black subjects	254
FIG. 4.68	Scatterplot of age and HDL cholesterol levels in white subjects	255
FIG. 4.69	Correlation between apo A- I and HDL cholesterol levels in black and white subjects	256
FIG. 4.70	Scatterplot of serum apo A-I, HDL cholesterol and ages in white subjects who were on Hormone Replacement Therapy	257
FIG. 4.71	Carbohydrate and fat consumption of black and white subjects who had HDL to total cholesterol ratios lower than 20%	259
FIG. 4.72	Scatterplot of carbohydrate and fat consumption of black	260

	and white subjects who had HDL to Total cholesterol ratios higher than 30%	
FIG. 4.73	Correlation between triglyceride levels and the size of LDL cholesterol particles in white subjects	266
FIG. 4.74	Correlation between triglyceride and glucose levels in black subjects	266
FIG. 4.75	Scatterplot of insulin and leptin levels in black and white subjects with BMI values greater than 35 kg/m ²	268
FIG. 4.76	Correlation between visceral fat and fasting glucose levels in black subjects	273
FIG. 4.77	Correlation between visceral fat and fasting glucose levels in non - diabetic black subjects	273
FIG. 4.78	Visceral fat areas in females with BMIs < 26 kg/m ² compared to visceral fat areas in females with BMIs > 26 kg/m ² (adapted from Enzi <i>et al.</i> , 1986)	276
FIG. 4.79	Retrospective comparison of BMI levels of black and white subjects at the ages of 18; 25 and 40 years according to their current fasting glucose levels	277
FIG. 4.80	Plasma insulin responses during 4 hour glucose tolerance tests in black subjects varying in body fat and glucose tolerance (adapted from Shires, Joffe & Seftel, 1978)	280
FIG. 4.81	Scatterplot of fasting insulin and fasting glucose levels in black subjects	280
FIG. 4.82	Scatterplot of birth mass and fasting glucose levels in black and white subjects	281
FIG. 4.83	The vicious circle of insulin resistance	283
FIG. 4.84	Uric acid levels of black and white subjects in the present study in comparison with that of different other female populations in South Africa	284
FIG. 4.85	Comparison of insulin levels in black and white subjects according to their uric acid levels	285
FIG. 4.86	Comparison of triglyceride levels in black and white subjects according to their uric acid levels	286
FIG. 4.87	Scatterplot of mean blood pressure and fasting glucose levels of black and white subjects with suspected microalbuminuria	288
FIG. 4.88	Correlation between albumin creatinine ratios and LDL particle size in white subjects	290
FIG. 4.89	Correlation between albumin creatinine ratios and triglyceride levels in white subjects	291
FIG. 4.90	Comparison of insulin levels in black subjects according to the number of their metabolic risk factors	295
FIG. 4.91	Comparison of triglyceride levels in black subjects according to the number of their metabolic risk factors	296
FIG. 4.92	Comparison of insulin levels in white subjects according to the number of their metabolic risk factors	297

FIG. 4.93	Comparison of triglyceride levels in white subjects according to the number of their metabolic risk factors	298
FIG. 4.94	Comparison of HDL/Total cholesterol ratios in black subjects according to the number of their metabolic risk factors	299
FIG. 5.1	The effect of regular exercise on cardiovascular risk factors (adapted from Schwellnus, 1994)	310

ACE inhibitors	Angiotensin Converting Enzyme inhibitors
ACh	Acetylcholine
ADH	Adrenomedullin
ADP	Adenosine Diphosphate
ALLHAT	Anti-hypertensive and Lipid Lowering to Prevent Heart Attack Trial
Ang II	Angiotensin II
ANP	Atrial Natriuretic Peptide
Apo B	Apoprotein B-100
ARIC study	Atherosclerosis Risk in Communities study
AT1	Angiotensin I
AT2	Angiotensin II
AVAV	Atrial Ventricular Third Venous
AVP	Arginine Vasopressin
BMI	Black female
Bradykinin	Bradykinin
BM	Body Mass Index
BMI	British Nutrition Foundation
BW	Body weight
C	Cholesterol
CAD	Coronary artery disease
CAMP	Cyclic Adenosine Monophosphate
CE	Cholesterol ester
CEBP	Cholesterol ester transfer protein
CHAOS	Cambridge Heart Antioxidant Study
CGMP	Cyclic Guanosine Monophosphate
CHD	Coronary Heart Disease
CHC study	Community Hypertension Evaluation Study
Chytomirons	Chytomirons
CRIS study	Coronary Risk Factor Study
CRP	C-reactive protein
CT	Computed tomography
DD	Body density
DBP	Diastolic Blood Pressure
DHA	Dihomo-gamma-linolenic acid
DHA	Docosahexaenoic Acid
DHEA	Dehydroepiandrosterone

List of abbreviations

% BF	Percentage body fat
5-HT ₁	5-Hydroxytryptamine-1
A/C	Albumin Creatinine ratio
AA	Arachidonic Acid
AAR	Alliance for aging research
ACE inhibitors	Angiotensin Converting Enzyme inhibitors
Ach	Acetylcholine
ACTH	Corticotropin
ADP	Adenosine Diphosphate
ALLHAT	Anti-hypertensive and Lipid-lowering to Prevent Heart Attack Trial
ANG II	Angiotensin II
ANP	Atrial Natriuretic Peptide
Apo B	Apoprotein B-100
ARIC study	Atherosclerosis Risk in Communities study
AT I	Angiotensin I
ATG	Angiotensinogen
AV3V	Anteroventral Third Ventricle
AVP	Arginine Vasopressin
BF	Black females
BK	Bradykinin
BMI	Body Mass Index
BNF	British Nutrition Foundation
BW	Body weight
C	Cholesterol
CAD	Coronary artery disease
CAMP	Cyclic Adenosine Monophosphate
CE	Cholesterol ester
CETP	Cholesterol ester transfer protein
CHAOS	Cambridge Heart Anti-oxidant Study
CGMP	Cyclin Guanosin Monophosphate
CHD	Coronary Heart Disease
CHEC study	Community Hypertension Evaluation Clinic study
CM	Chylomicrons
CORIS study	Coronary Risk Factor Study.
CRF	Corticotropin-releasing hormone
CT	Computed tomography
Db	Body density
DBP	Diastolic Blood Pressure
DGA	Dihomo-gammalinolenic acid
DHA	Docosahexaenoic Acid
DHEA	Dehydroepiandrosterone

ECE	Endothelin Converting Enzyme
ECF	Extracellular Fluid
EDHF	Endothelium-derived Hyperpolarizing Factor
EDNO	Endothelium-derived nitric oxide
EDRF	Endothelium-derived Relaxing Factor
EE	Energy Expenditure
EFA	Essential Fatty Acid
EOLS	Endogenous Ouabain-like Substances
EPA	Eicosapentaenoic Acid
Factor VIIc	Coagulent activity of Factor VII
FAI	Functional Aerobic Impairment
FFA	Free Fatty Acid
FSH	Follicle stimulating hormone
FT	Fast Twitch fibres
GH	Growth hormone
GHRH	Growth hormone releasing hormone
GLA	Gamma Linolenic Acid
Glucose-6-P	Glucose 6 Phosphate
HDL cholesterol	High-density lipoprotein cholesterol
HL	Hepatic lipase
HOMA	Homeostasis Model Assessment
HOT study	Hypertension Optimal Treatment study
HPA axis	Hypothalamo-pituitary-adrenal axis
HT	Height
IBM	Ideal Body Mass
IDDM	Insulin Dependent Diabetes Mellitus
IDL	Intermediate Density Lipoprotein
IGF I	Insulinlike Growth Factor I
IMT	Intimal-medial thickness
ISH	Isolated Systolic Hypertension
ISH	International Society for Hypertension
J-G	Juxtaglomerular
JNC	Joint National Committee on the Detection Evaluation and Treatment of High Blood Pressure
L-arg	L-arginine
LA	Linoleic Acid
LCAT	Lecithin-cholesterol acetyl transferase
LDL cholesterol	Low density lipoprotein cholesterol
LH	Luteinizing hormone
Lp (a)	Lipoprotein a
LPL	Lipoprotein Lipase
LRC	Lipid Research Clinics
LVH	Left ventricular hypertrophy

MARS	Monitored Atherosclerosis Regression Study
MBP	Membrane Binding Protein
MRC	Medical Research Council
n-3	omega 3 poly-unsaturated fatty acid
n-6	omega 6 poly-unsaturated fatty acid
NEFA Non	esterified fatty acids
NHANES I	National Health and Nutrition Examination Survey I
NIDDM	Non-insulin dependent diabetes mellitus
NO	Nitric Oxide
PAI I	Plasminogen activator inhibitor I
PG	Prostaglandin
PGI ₃	Prostacyclin
PHYLLIS	Plaque Hypertension Lipid Lowering Italian Study
PL	Phospholipids
POMS	Profile of Mood States
PRA	Plasma Renin Activity
PUFA	Poly-unsaturated Fatty acid
PV	Plasma Volume
RDA	Recommended dietary allowance
RIA	Radioimmunoassay
RR	Relative risk
SAG	Sagittal height
SANSS	South African Nutritional Status Survey
SBP	Systolic Blood Pressure
Sf	Svedberg unit
SHEP	Systolic Hypertension in the Elderly Program
SKF	Skinfold
SNS	Sympathetic Nervous System
SPSS	Statistical Package for Social Sciences
ST	Slow Twitch fibers
t-PA	Tissue plasminogen activator
TEE	Total Energy Expenditure
TG	Triglyceride
TGF	Transforming Growth Factor
TGRLP	Triglyceride Rich Lipoprotein
Thr	Thrombin
TMD	Total Mood Disturbances
UAER	Urinary albumin excretion rate
UBO	Upper Body Obesity
UK	United Kingdom
USA	United States of America
VIGHOR	Vanderbijlpark Information project re: Gezondheid/Health Obesity Risk Factors

VLDL	Very Low Density Lipoprotein
WF	White females
WHO	World Health Organization
WHR	Waist-to-hip ratio

SUPERVISOR: Prof J.M. Loria

DEPARTMENT: Department of Biometrics, Sport and Leisure Sciences

DEGREE: DPhil

There seems to be a dearth of information on insulin related coronary heart disease risk factors in South Africa. The main objective of the present study therefore was to determine if the lifestyles and body fat distributions of black and white hypertensives increase their susceptibility to insulin resistance and CVD. This information may be used to optimize anti-hypertensive therapy and reduce their overall CVD risk.

A total of 60 females (30 black and 30 white) with blood pressure $\geq 160/95$ mmHg were recruited in the Pieterburg area. Their physical activity was assessed with a questionnaire developed by Paffenbarger et al (1978). A self-administered frequency questionnaire was used to collect information on their physical activity. Aerobic capacity of the subjects was measured indirectly with a 30 min cycle test. Overall obesity levels were made body fat and fat distribution by standard anthropometric measurements such as body mass index (BMI), waist-hip ratio (WHR) and sagittal height. Body composition was determined by computed tomography (CT) scans and ultrasound. Serum lipids were measured on overnight fasting blood samples. Lipoproteins, insulin, glucose, triglycerides, plasminogen and fibrin, albumin and creatinine levels were measured on fasting samples. Insulin resistance was calculated from fasting glucose and insulin according to the computer solved homeostasis model of Petersen et al (1999).

SINOPSIS

TITLE: Lifestyle, body fat distribution and insulin-related coronary heart disease risk factors in hypertensive females

NAME OF CANDIDATE: L.A.S. du Plessis

SUPERVISOR: Prof J.M. Loots

DEPARTMENT: Department of Biokinetics, Sport and Leisure Sciences

DEGREE: DPhil

There seems to be a dearth of information on insulin related coronary heart disease risk factors in South-Africa. The main objective of the present study therefore, was to determine if the lifestyles and body fat distributions of black and white female hypertensives increase their susceptibility to insulin resistance and CHD. Such information may be used to optimize anti-hypertensive treatment of females and to lower their overall CHD risk.

A total of 60 females (30 black and 30 white) with uncomplicated essential hypertension were recruited in the Pietersburg area. Their physical activities and health were assessed with a questionnaire developed by Paffenbarger *et al.* (1993). A quantitative food frequency questionnaire was used to collect information on their habitual diets. The aerobic capacity of the subjects was measured indirectly with a 1 mile walking test. Overall obesity levels, percentage body fat and fat distribution were measured with standard anthropometric measurements such as body mass index (BMI), sum of skinfolds, waist-to-hip ratios (WHR) and sagittal heights. Abdominal fat was measured with computed tomography (CT) scans and ultrasound (sonars). The following tests were done on overnight fasting blood samples: full lipograms, insulin, glucose, uric acid, fibrinogen, plasminogen and leptin. Albumin and creatine levels were measured in random urine samples. Insulin resistance was calculated from fasting glucose and insulin concentrations according to the computer-solved homeostasis model of Matthews *et al.* (1985): Insulin

resistance = insulin/ (22.5e^{linglucose}).

Although black and white subjects in the present study were equally obese with similar WHRs, CT scans revealed that white subjects carried more intra-abdominal fat and black subjects more subcutaneous abdominal fat. This may explain why twice as many white subjects (17 vs 8) had large insulin related CHD risk clusters. Obesity thus seems to be more benign in the majority of black females, but those with a propensity for visceral accumulation, may be particularly at risk of CHD. They not only matched their white counterparts, as far as the sizes of their intra-abdominal fat areas and the number of their CHD risk factors are concerned, but they were all diabetic as well. The different fat distributions of black and white subjects could not be explained by differences in their diets, smoking, drinking and stress levels, but it should be noted that aerobic capacity showed strong inverse correlations with visceral fat areas in both groups. Although these correlations may be epiphenomena of genetic factors, it can be envisaged that an increase in aerobic activity would not only decrease the visceral fat areas of most subjects, but it would also improve their insulin sensitivity and CHD metabolic risk profiles. These prophylactic effects of aerobic exercise would be enhanced even more by a decrease in sugar, refined carbohydrates and saturated fat intake and an increased intake of fish and whole foods containing complex carbohydrates. For some females even assiduous attention to diet, body mass control and exercise may not be enough to lower their CHD risk significantly and they should seriously consider supplementation with vitamin E, C and B complex.

Key words: hypertension, diet, physical activity, stress, insulin resistance syndrome, coronary heart disease, obesity, computed tomography, ultrasound, body fat distribution, visceral fat, type 2 diabetes.

SAMEVATTING

TITEL: Lewenstyl, verspreiding van liggaamsvet en insulienverwante risikofaktore vir koronêre hartsiekte in hipertensiewe vroue

NAAM VAN KANDIDAAT: L.A.S. du Plessis

STUDIELEIER: Prof. J.M. Loots

DEPARTEMENT: Biokinetika, Sport-en Vryetydwetenskappe

GRAAD: D. Phil.

Dit wil voorkom asof daar 'n gebrek aan inligting aangaande insulienverwante risikofaktore vir koronêre hartsiekte in Suid-Afrika is. Die hoofdoel van die huidige studie was dan juis om te bepaal of die lewenstyl en liggaamsvetverspreiding van swart - en wit hipertensiewe vroue hulle vatbaarheid vir insulienweerstand en koronêre hartsiekte verhoog. Hierdie inligting kan gebruik word om anti-hipertensiewe behandeling te optimaliseer en om algehele koronêre risiko te verlaag.

Sestig vroue (30 swart en 30 wit) met ongekompliseerde essensiële hipertensie is in die Pietersburgdistrik gewerf. Hulle fisieke aktiwiteit en gesondheid is geëvalueer deur 'n vraelys wat deur Paffenbarger *et al.* (1993) ontwikkel is. 'n Kwantitatiewe voedselrekwensievraelys is gebruik om inligting in te samel oor die kos wat hulle normaalweg eet. Die aërobiese kapasiteit van die proefpersone is op indirekte wyse gemeet met 'n 1-myl staptoets. Algehele obesiteitsvlakke, persentasie liggaamsvet en vetverspreiding is gemeet met standaard antropometriese metings soos liggaamsmassa-indeks, som van velvoudiktes en middel-tot-heupomtrek-ratio's. Abdominale vet is gemeet met gerekenariseerde aksiale tomografiese skandering en ultraklank (sonar). Die volgende bloedtoetse is gedoen op oornagse vastende bloedmonsters: vol lipogramme, insulien, glukose, uriensuur, fibrinogeen, plasminogeen en leptien. Albumien- en kreatinienvlakke is gemeet in lukraakgekose urienmonsters. Insulienweerstand is bepaal vanaf vastende glukose- en insulienkonsentrasies volgens die homeostaserekenaarmodel van Matthews

et al. (1985): Insulienweerstand = insulien/ (22.5e^{linglukose}).

Alhoewel swart - en wit proefpersone in hierdie studie ewe obees was met soortgelyke middel-tot-heupratio's, het skandering gewys dat wit vroue meer intra-abdominale, en swart vroue meer onderhuidse abdominale vet dra. Dit mag dalk verklaar hoekom tweemaal soveel wit - as swart proefpersone (17 vs 8) hoë insulienverwante koronêre risikogroeperinge gehad het. Obesiteit blyk dus meer onskadelik te wees in die meerderheid swart vroue, maar dié met 'n geneigdheid tot akkumulering van viserale vet, mag 'n besonderse hoë risiko hê vir koronêre hartsiekte. Hulle was nie net op gelyke voet met hulle wit eweknieë in terme van die grootte van hulle viserale vetoppervlaktes en hoeveelheid koronêre risikofaktore nie, maar hulle was boonop almal diabeties. Die verskil in vetverspreiding van swart - en wit vroue kon nie verklaar word deur verskille in hulle diëte, rook- en drinkgewoontes en stresvlakke nie, maar daar moet op gelet word dat aërobiese kapasiteit sterk negatiewe korrelasies toon met viserale vetoppervlakte in beide groepe. Alhoewel hierdie korrelasies slegs epifenomena van genetiese faktore kon wees, sou mens kon verwag dat 'n verhoging in aërobiese kapasiteit nie net sou gepaardgaan met 'n krimpings in viserale vetoppervlaktes in meeste proefpersone nie, maar ook met verhoogde insulien sensitiwiteit en 'n beter koronêre risikoprofiel. Die profilaktiese effek van aërobiese oefening kan verder verhoog word deur 'n afname in suiker, verfynde koolhidraat en versadigde vetname, gepaardgaande met 'n toename in vis, asook kos wat bestaan uit gekompliseerde koolhidrate. Vir sommige vroue mag volharding met die regte dieet, massabeheer en oefening selfs nie genoeg wees om hulle koronêre risiko beduidend te verlaag nie, en hulle behoort dit ernstig te oorweeg om aanvullende vitamien E, C en B kompleks in te neem.

Sleuteltermes: hipertensie, dieet, fisieke aktiwiteit, stres, insulienweerstandssindroom, koronêre hartsiekte, obesiteit, gerekenariseerde aksiale tomografiese skandering, ultraklank, liggaamsvetverspreiding, viserale vet, tipe 2- diabetes.